Finding patients who qualify for a clinical trial has always been one of the hardest parts of running one. In liver disease, particularly MASLD, it is especiall...
Continue reading
More than three decades after the Huntington's disease gene was cloned in 1993, there is still no approved therapy that alters the course of the disease. Recent...
Continue reading
When a clinical trial misses its enrollment targets, the instinct is often to look at recruitment through more channels, more outreach, and a bigger advertising...
Continue reading
In the most recent episode of The Genetics Podcast, host Patrick Short speaks with Dr. Paul Valdmanis, Associate Professor at the University of Washington, abou...
Continue reading
What four episodes of The Genetics Podcast reveal about the future of Alzheimer’s precision medicine
Alzheimer’s research is entering a new phase. For decades, the field has been shaped by the biology of amyloid plaques and tau tangles. Those remain central to ...
Continue reading
In the most recent episode of The Genetics Podcast, Patrick Short speaks with Dr. Sarah Marzi, Senior Lecturer at King’s College London and Group Leader at the ...
Continue reading
Precision medicine sponsors invest heavily to identify, educate, screen, consent, genotype, and support rare patients. In many programs, once a trial ends, that...
Continue reading
UK Biobank and similar resources have made an extraordinary contribution to biomedical research, enabling important advances across genomics, population health,...
Continue reading
Recruitment in precision medicine and rare disease trials remains constrained by fragmented data, low prevalence populations, and heavy reliance on site-based p...
Continue reading
On the latest episode of The Genetics Podcast, Patrick Short speaks with Dr. Suzanne Schindler associate professor of neurology at Washington University in St. ...
Continue reading
Rare disease exposes the limits of current clinical development models. Small, fragmented populations make patient identification difficult. Heterogeneous biolo...
Continue reading
Rare disease drug development involves decision-making under extreme uncertainty. Teams are asked to design trials without well-established endpoints, in small ...
Continue reading
Liver disease remains one of the few major disease areas where outcomes have not improved in line with other fields such as cardiovascular disease and cancer. I...
Continue reading
In rare disease and genetically stratified trials, recruitment often depends on a single critical step: confirming that a patient carries the relevant genetic v...
Continue reading
Genetic testing has become a core component of patient identification and stratification in modern clinical trials, particularly in rare disease and precision m...
Continue reading
On the latest episode of The Genetics Podcast, Patrick welcomed Dr. Andrea Ganna, an Associate Professor at the Institute for Molecular Medicine Finland (FIMM),...
Continue reading
At Seqera Sessions London 2026, Dr. Katie Barnes, Head of Clinical Genetics at Sano Genetics, outlined a practical challenge facing the field: how to move from ...
Continue reading
Recruitment in genetically stratified clinical trials is often constrained by a simple problem: large screening volumes do not translate into eligible patients....
Continue reading
Somerset, UK, 18th March 2026: Predictive Health Intelligence (PHI) and Sano Genetics today announced the completion of recruitment into the LiveWell study, wit...
Continue reading
Genome sequencing is now a core part of rare disease diagnostics in several healthcare systems. However, the path from sequencing technology to clinical impact ...
Continue reading
Recruiting and retaining patients in rare disease and genomic medicine research requires more than outreach. Many participants need support understanding geneti...
Continue reading
Genetic screening has advanced rapidly over the past two decades. Sequencing is faster and far less expensive, and the ability to interpret genetic variants con...
Continue reading
Rare disease trials operate under structural constraints that make site selection more important than in common disease programs. Patient populations are small,...
Continue reading
Rare disease innovation has accelerated in recent years, particularly in cell and gene therapy (CGT). Yet for drug developers, one challenge remains persistent:...
Continue reading
In a recent episode of The Genetics Podcast, Patrick Short spoke with Dr. Ryan Dhindsa, Assistant Professor at Baylor College of Medicine and Investigator at th...
Continue reading
The majority of rare disease discovery has been linked to protein coding genes, where changes are easier to interpret and easier to capture in routine testing. ...
Continue reading
Adeno-associated virus (AAV) gene therapy has moved from proof of concept to approved products. As more programs enter the clinic and target larger patient popu...
Continue reading
Cell and gene therapy (CGT) programs are committing to 10-15 years of follow-up – often without the infrastructure to support it. FDA guidance for certain gene ...
Continue reading
In the latest episode of The Genetics Podcast, we spoke with Dr. Daniel Chung, Chief Medical Officer at Beacon Therapeutics. The conversation focused on how ret...
Continue reading
Digital recruitment has become a standard part of clinical trial execution. Sponsors invest heavily in online outreach, patient referrals, and awareness campaig...
Continue reading
Last week, the rare disease field celebrated another breakthrough. A teenage girl with an ultra-rare genetic neurodegenerative disease was treated with a bespok...
Continue reading
As genetic medicine has continued to advance, experts have consistently highlighted the importance of newborn genomic screening as a practical avenue for early ...
Continue reading
Patient availability is often overestimated during trial planning. This usually starts at feasibility, where sites are asked to report how many patients they ha...
Continue reading
At the JPM Healthcare Conference 2026, the Genetics Podcast recorded a special episode from the Flagship Pioneering studio, bringing together two leaders advanc...
Continue reading
Trial sponsors often assume that site enablement is largely complete once a trial launches. Feasibility assessments, training materials, and startup timelines a...
Continue reading
Cell and gene therapy continues to advance across a growing number of rare genetic conditions. As more of these therapies move closer to the clinic, a central t...
Continue reading
Rare and genetic programs increasingly depend on healthcare systems that are still adapting to the demands of precision medicine. Many of the constraints that a...
Continue reading
In a recent episode of The Genetics Podcast, host Patrick Short talked with Dr. Arabella Bouzigues, postdoctoral researcher and coordinator of the Genetic Front...
Continue reading
Regulatory expectations in genomics-driven drug development are evolving alongside scientific practice, clinical implementation, and policy. While formal guidan...
Continue reading
In the latest episode of The Genetics Podcast, Patrick spoke with Lisa Gurry, Chief Business Officer at GeneDx. The conversation focuses on how GeneDx has built...
Continue reading
Over the past few years, several cell and gene therapies (CGTs) in precision medicine have received FDA Complete Response Letters (CRLs). As the agency increase...
Continue reading
In the latest episode of The Genetics Podcast, Patrick spoke with Dr. Jeffrey Chamberlain, Professor at the University of Washington School of Medicine and Dire...
Continue reading
The FDA’s activity in 2025 reflected a mix of scientific progress and operational instability. Precision medicine programs benefitted from new draft guidance, r...
Continue reading
Recruitment for genetically stratified clinical trials is a critical bottleneck for sponsors. Identifying individuals with specific variants, building trust aro...
Continue reading
In the last episode of The Genetics Podcast, Patrick spoke with Dr. Rachel Salzman, CEO of Armatus Bio, a biotech company developing vectorized RNA interference...
Continue reading
Psychiatric precision medicine has been a promising area of research for nearly two decades, but only recently has data emerged that can influence real clinical...
Continue reading
In the last episode of The Genetics Podcast, Patrick spoke with Dr. Slavé Petrovski, Vice President of AstraZeneca’s Center for Genomics Research. Slavé oversee...
Continue reading
Spatial omics have revolutionized biomedical research in recent years. The use of spatial techniques unlocks cell-specific understanding of disease, which suppo...
Continue reading
At Sano, every product, pipeline, and participant experience depends on secure, reliable, and scalable infrastructure. That foundation is shaped by our platform...
Continue reading
In the last episode of The Genetics Podcast, we spoke with Dr. Ellen Reisinger, Professor at the University of Tübingen. Ellen has spent nearly twenty years stu...
Continue reading
Recent activity in the US and UK offers important signals for how personalized and rare disease therapies may evolve. Scientific teams are building structured e...
Continue reading
At the recent Evolution of the Cell and Gene Therapy (CGT) Sector Workshop by the Alliance for Regenerative Medicine (ARM), speakers from across industry, acade...
Continue reading
On the latest episode of The Genetics Podcast, we spoke with Ananth Sridhar, Chief Operating Officer for cardiorenal programs at BridgeBio, and Sun-Gou Ji, the ...
Continue reading
AI is becoming a core component of drug development and clinical research. Models are improving and regulatory frameworks are evolving, but progress still depen...
Continue reading
In drug discovery, data is the key to success. Although more and more large-scale data is being generated every year, much of it is inaccessible or fragmented. ...
Continue reading
In the last episode of The Genetics Podcast, Patrick spoke with Justin Porcano, co-founder and executive director of Save Sight Now, a nonprofit accelerating th...
Continue reading
Gene editing has progressed significantly over the past decade, evolving from an experimental technology that was associated with safety and efficacy limitation...
Continue reading
In a special live episode of The Genetics Podcast, recorded at the American Society of Human Genetics (ASHG) meeting, host Patrick Short was joined by two of th...
Continue reading
On this episode of The Genetics Podcast, Patrick spoke with Chris Hopkins, CEO of Glafabra Therapeutics, a company developing a one-time autologous cell therapy...
Continue reading
At this year’s European Society of Gene & Cell Therapy (ESGCT) meeting, one theme resonated across sessions: adeno-associated viruses (AAVs) are entering a ...
Continue reading
Participation in clinical trials can be burdensome and disruptive. In addition to practical inconveniences and discomfort, participants may have to take time of...
Continue reading
On the most recent episode of The Genetics Podcast, host Patrick Short took a solo deep dive into gene therapy, with a focus on therapies based on delivery via ...
Continue reading
Study start-up is a critical stage of the drug development process and can have a major impact on trial timelines, budgets, and overall success. Start-up activi...
Continue reading
Podcast recap: Sonya Dumanis and Andy Singleton on building a global genetics engine for Parkinson’s
On the most recent episode of The Genetics Podcast, we hosted Sonya Dumanis and Andy Singleton to unpack GP2, the Global Parkinson’s Genetics Program. GP2 is a ...
Continue reading
At the Partnerships with Sites summit in September 2025, new data from the Tufts Center for the Study of Drug Development (Tufts CSDD) underscored how the globa...
Continue reading
Advocating for patients is one of the core pillars of Sano’s mission. Our approach to clinical trials is patient-centered and entails deep and meaningful engage...
Continue reading
Rare disease trials are among the most challenging to design and execute. Patient populations are small and hard to reach, and personal and disease-related burd...
Continue reading
In last week’s episode of The Genetics Podcast, Patrick Short sat down with Wanda Smith, founder of CureGRN and long-time advocate for families affected by prog...
Continue reading
At this year’s DPHARM conference, Sano’s VP of Commercial, Ben Jackson, joined a panel on clinical trial patient matching moderated by a clinical expert from No...
Continue reading
On the most recent episode of The Genetics Podcast, we hosted Terry Pirovolakis, founder and CEO of Elpida Therapeutics. Terry’s journey began the day his young...
Continue reading
At Sano, our mission is to accelerate precision medicine research through technology, making it easier for sponsors to run trials efficiently and effectively. E...
Continue reading
Natural history studies are central to rare disease research. Rare diseases are defined as conditions that affect less than 1 in 200,000 people in the US or les...
Continue reading
On the most recent episode of The Genetics Podcast, Patrick speaks with Samuli Ripatti, director of the Institute for Molecular Medicine Finland (FIMM) and prof...
Continue reading
On the latest episode of The Genetics Podcast, Patrick sat down with Jonathan Marchini, Head of Statistical Genetics & Machine Learning at the Regeneron Gen...
Continue reading
On the latest episode of The Genetics Podcast, Patrick speaks with Max Bronstein, founder and CEO of Aviva Strategies, a health policy firm dedicated to support...
Continue reading
Genetic medicines have been advancing at an extraordinary pace. Following the first wave of adeno-associated virus (AAV)–based gene therapies, the toolbox for g...
Continue reading
The next generation of advanced therapies, particularly gene therapies, hold enormous promise for patients with rare conditions. However, their clinical develop...
Continue reading
In this week’s episode of The Genetics Podcast, we spoke with Richard Wilson, Senior Vice President and Primary Focus Lead for Genetic Regulation at Astellas, a...
Continue reading
Precision medicine trials increasingly depend on genetic or biomarker testing to determine eligibility. Each additional test introduces operational complexity: ...
Continue reading
In rare disease, families are often forced into roles that extend far beyond caregiving. When faced with diseases for which no treatment exists, parents have of...
Continue reading
Last week marked a major milestone for The Genetics Podcast: our 200th episode. To celebrate, host Patrick Short revisited some of the most impactful conversati...
Continue reading
In recent years, the therapeutic landscape for genetic hearing loss (GHL) has advanced rapidly, with several programs reaching clinical development. However, tr...
Continue reading
In the last episode of the Genetics Podcast, Patrick speaks with Dr. Xin Jin, a pioneering neuroscientist at Scripps Research, about her team’s cutting-edge met...
Continue reading
After a decade of strong investment, the biotech sector in 2025 is navigating a markedly constrained funding environment. Early-stage companies, particularly th...
Continue reading
Clinical trials have always been burdensome on sponsors, but in the current biotech landscape, the pressure to execute trials promptly, efficiently, and in a co...
Continue reading
In the latest episode of The Genetics Podcast, we sat down with Dr. Benny Sorenson, CEO of Hemab Therapeutics, to explore a relatively overlooked therapeutic ar...
Continue reading
The promise of precision medicine has been intensifying over the past decade. In 2025, the field appears to be at an inflection point due to a confluence of var...
Continue reading
In the latest episode of The Genetics Podcast, we spoke with Dr. Heiko Runz, SVP of Neuroscience at insitro. With a background spanning clinical genetics, acade...
Continue reading
As part of new efforts to improve FDA processes and enhance communication with stakeholders, they hosted a roundtable on cell and gene therapy on June 5th, 2025...
Continue reading
In the latest episode of The Genetics Podcast, we spoke with Dr. Molly He, CEO and co-founder of Element Biosciences. With over a hundred patents and leadership...
Continue reading
At Sano, data is at the core of everything we do. From mining our patient database to identify patients for trials to analyzing sequencing data, our engineering...
Continue reading
In the latest episode of The Genetics Podcast, we had a captivating conversation with Dr. David Bumcrot, Chief Scientific Officer at CAMP4 Therapeutics. From he...
Continue reading
At Sano Genetics, our mission is to deliver and facilitate clinical trials that accelerate the development of precision medicine treatments for patients. As a c...
Continue reading
In a recent episode of The Genetics Podcast, Dr. Melissa Haendel, Director of Translational Informatics and Precision Health and Professor at the University of ...
Continue reading
In a recent episode of The Genetics Podcast, Dr. Huma Qamar, Chief Medical Officer at Ocugen, shares her extraordinary journey from a small town in Pakistan to ...
Continue reading
In a recent episode of The Genetics Podcast, we talked to Frank Gentile, Chief Executive Officer of Casma Therapeutics, to explore how autophagy could be a valu...
Continue reading
Technological advances and biomedical breakthroughs have triggered a paradigm shift in precision medicine. Clinical research is currently at a turning point at ...
Continue reading
In May and June of 2025, the Food and Drug Administration (FDA) announced a series of developments related to the use of artificial intelligence (AI) across its...
Continue reading
Duchenne muscular dystrophy (DMD) is an inherited disorder that is characterized by progressive muscle degeneration, leading to loss of function and premature d...
Continue reading
On a recent episode of The Genetics Podcast, Patrick was joined by Andres Moreno-Estrada, population geneticist and head of the Human Evolutionary Genomics Lab ...
Continue reading
We recently attended the GBA1 conference in Montreal, which brought together researchers, clinicians, biotech leaders, and patient advocates to discuss cutting-...
Continue reading
Myasthenia gravis (MG) is a chronic neuromuscular disorder (NMD) that is characterized by muscle fatigue and weakness. It is considered a rare disease, affectin...
Continue reading
On a recent episode of The Genetics Podcast, Patrick spoke with Frank Gleeson, co-founder and CEO of Satellos Bioscience, a Canadian biotech pioneering a regene...
Continue reading
At Sano Genetics, our mission is to make clinical research in precision medicine faster, more inclusive, and more efficient. In our Q2 2025 product webinar, we ...
Continue reading
Precision medicine has fundamentally changed how diseases are defined and how therapies are developed — shifting eligibility from clinical phenotype to molecula...
Continue reading
On a recent episode of The Genetics Podcast, Patrick spoke with Tim Spector, Professor of Genetic Epidemiology at King’s College London and co-founder of Zoe. T...
Continue reading
Biomarker testing is foundational to precision medicine. It determines eligibility for targeted therapies and immunotherapies, informs treatment selection, and ...
Continue reading
As the demand for personalized therapies continues to grow, trial designs must evolve to reflect the biological variability between patients. Traditional models...
Continue reading
On a recent episode of The Genetics Podcast, Patrick spoke with Daniel Geschwind, Senior Associate Dean and Associate Vice Chancellor of Precision Health at UCL...
Continue reading
News of a ‘CRISPR baby’ broke this week, almost seven years after the first CRISPR baby scandal unleashed a media frenzy and years of ethical debates. But this ...
Continue reading
Although long COVID cases have surged in recent years, the genetic factors that influence who develops the condition remain poorly understood. Traditional genom...
Continue reading
We’re proud to share that Sano Genetics plays a key role in the newly announced Lupus Nexus Foundational Analyses, a groundbreaking initiative led by the Lupus ...
Continue reading
Site disengagement can be a major barrier to successful and timely trial execution. A significant contributor to disengagement is overloading sites with redunda...
Continue reading
Clinical trial recruitment is notoriously difficult, and nowhere is this more acute than at the referral stage. When a participant who looks potentially eligibl...
Continue reading
In the most recent episode of the Genetics Podcast, Patrick spoke with Helen O’Neill, a molecular geneticist who is the founder of Hertility Health and an assoc...
Continue reading
Fostering and maintaining a high standard for site engagement are key priorities for sponsors as they can enhance the likelihood of effective and timely trial e...
Continue reading
Clinical trial recruitment remains one of the most persistent bottlenecks in drug development. Across therapeutic areas, trials routinely face delays, cost over...
Continue reading
While there have been significant strides in the development of drugs for rare diseases over the past few decades, only 5% of rare diseases have FDA-approved tr...
Continue reading
In the most recent episode of The Genetics Podcast, Patrick speaks with Dr. Madhuri Hegde, SVP and Chief Scientific Officer at Revvity. Madhuri’s work has helpe...
Continue reading
.png)
In a recent episode of The Genetics Podcast, Patrick Short sits down with Dr. Euan Ashley, Chair of Medicine at Stanford University, author of The Genome Odysse...
Continue reading
In a recent episode of The Genetics Podcast, Patrick spoke with Kent Rogers, CEO of EveryONE Medicines, about the future of individualized medicines, especially...
Continue reading
Precision medicine has the potential to transform how we understand and treat autoimmune and inflammatory diseases, but only if we can align innovation with inf...
Continue reading
The way we treat autoimmune and inflammatory diseases is undergoing a fundamental shift. These conditions are deeply heterogeneous. Patients with the same diagn...
Continue reading
Podcast recap: Matt Burgess on genetic counseling, ethics in rare disease, and demystifying genetics
In the most recent episode of The Genetics Podcast, Patrick sits down with fellow podcaster and genetic counselor Matt Burgess. Matt is the host of Demystifying...
Continue reading
Autoimmune diseases include more than 80 conditions defined by immune system dysfunction in which the body mistakenly attacks healthy tissue. Treating autoimmun...
Continue reading
Despite growing momentum behind precision medicine, autoimmune and inflammatory diseases remain some of the most underserved areas in healthcare. Affecting an e...
Continue reading
In a recent episode of The Genetics Podcast, Patrick spoke with Dr. Sal Rico, Chief Medical Officer at Encoded Therapeutics. Having worked across small molecule...
Continue reading
Precision medicine offers more targeted treatments, better patient outcomes, and even the potential to transform how we approach disease. But getting there isn’...
Continue reading
In rare and ultra-rare diseases, data availability is one of the most significant constraints in research and drug development. With thousands of rare condition...
Continue reading
As clinical trials become more complex and patient populations more diverse, the traditional focus on recruitment alone is no longer enough. Building long-term ...
Continue reading
In the latest episode of The Genetics Podcast, Patrick Short chatted with Leeland Ekstrom, CEO and co-founder of Nashville Biosciences (NashBio), a for-profit s...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short sat down with Sharon Terry, the CEO of Genetic Alliance, to discuss her extraordinary journey ...
Continue reading
Despite the huge potential of new technologies to enable precision approaches to diagnosing, managing, and treating genetic hearing loss, significant barriers a...
Continue reading
Hearing loss affects over 1.5 billion people worldwide, with nearly half of all cases linked to genetic factors. Despite this, diagnosis and treatment options h...
Continue reading
In the latest episode of The Genetics Podcast, Patrick spoke with Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. ProFound Therapeutics, ...
Continue reading
For decades, treatment for congenital and genetic hearing loss has largely relied on devices such as hearing aids and cochlear implants. While these technologie...
Continue reading
In the latest episode of The Genetics Podcast, Patrick spoke with Dr. Raghib Ali, CEO and CMO of Our Future Health (OFH), a UK initiative aimed at recruiting 5 ...
Continue reading
Diagnosing genetic hearing loss hasn’t always been straightforward. With so many different causes and overlapping symptoms, traditional methods have often strug...
Continue reading
In the most recent episode of The Genetics Podcast, Patrick Short sits down with Dr. Anthony Bleyer, Professor of Medicine at Wake Forest University, and Stan K...
Continue reading
In a recent episode of The Genetics Podcast, Patrick sat down with Michelle Werner, CEO of Alltrna and CEO Partner at Flagship Pioneering. If you’ve been follow...
Continue reading
.png)
In last week’s episode of The Genetics Podcast, Patrick spoke with Jocelynn Pearl, Director of Cancer Cell Therapy at the TAM Center. With a career spanning gen...
Continue reading
In precision medicine trials, recruitment and compliance are interdependent workstreams. Every step that brings a patient closer to enrollment, from digital out...
Continue reading
Most clinical trials fail to recruit enough participants on time. In rare disease and genetically stratified studies, the challenge is compounded: the patient p...
Continue reading
In last week’s episode of The Genetics Podcast, Patrick Short spoke with Dr. Eric Adler, Professor of Medicine at UC San Diego and Chief Medical Officer at Lexe...
Continue reading
In last week’s episode of The Genetics Podcast, Patrick sat down with Dr. Versha Pleasant, Clinical Assistant Professor at the University of Michigan and Direct...
Continue reading
Patient recruitment efforts are often designed with the best of intentions, incorporating processes that fulfill every regulatory requirement. However, without ...
Continue reading
On October 18th, 2024 20/20 Onsite, Sano Genetics, and Clinical Enrollment announced the launch of a new partnership to offer a comprehensive solution for ident...
Continue reading
.png)
In a recent episode of The Genetics Podcast, Patrick Short is joined by Dr. Jonathon Hill, Associate Professor at Brigham Young University and Co-Founder and VP...
Continue reading
Effective data management and innovative clinical trial designs are pivotal in advancing precision medicine, particularly for biotech companies operating with b...
Continue reading
We were excited to welcome Angela Bradshaw, Director of Research at Alzheimer Europe, to The Genetics Podcast this week. Angela shared her journey from academic...
Continue reading
Precision medicine is built on the premise that treatment and prevention strategies should account for individual variability in genes, environment, and lifesty...
Continue reading
Metabolic-associated steatotic hepatitis (MASH) is primarily managed through lifestyle modifications, such as adopting a restricted diet high in antiinflammator...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short is joined by Dr. Hilary Martin, Group Leader in Human Genetics at the Wellcome Sanger Institut...
Continue reading
Recently on The Genetics Podcast, Patrick sat down with Dr. Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences, to explore some of the most exciting...
Continue reading
Precision medicine approaches to cardiometabolic conditions are still in their infancy but stand poised to transform treatment approaches and are increasingly r...
Continue reading
Cardiovascular disease remains a leading global health concern, claiming millions of lives each year and disproportionately affecting communities worldwide. Fac...
Continue reading
In the latest episode of The Genetics Podcast, host and Sano Genetics CEO Patrick Short welcomes Dr. Eric Green, CEO and Founder of Trace Neuroscience. Eric has...
Continue reading
As of March 2023, 3,900 gene therapy trials were noted as ongoing, completed, or approved across 46 different countries. An analysis of the second quarter of 20...
Continue reading
There are strong indications that patient acceptance of cell and gene therapies increases significantly following the provision of clear, easy-to-understand inf...
Continue reading
Cell and gene therapies (CGTs) are reshaping what it means to treat disease. Instead of managing symptoms over a lifetime, these approaches aim to address disea...
Continue reading
Gene and cell therapies represent a fundamental shift in how rare diseases are treated. Rather than managing symptoms, these therapies target the underlying gen...
Continue reading
Rare disease drug development operates under a unique set of structural constraints. Patient populations are small and dispersed, diagnostic timelines are long,...
Continue reading
In a recent episode of The Genetics Podcast, Patrick Short hosted Dr. Nessan Bermingham, a scientist turned biotech entrepreneur and operating partner at Khosla...
Continue reading
There are a number of innovative tools and technologies which are enabling precision patient finding. From AI to e-consent, here we explore how they are changin...
Continue reading
In the latest episode of The Genetics Podcast, Patrick Short was joined by Dr. Luis Diaz, head of the Division of Solid Tumor Oncology at Memorial Sloan Ketteri...
Continue reading
On a recent episode of The Genetics Podcast, Patrick Short speaks with Dr. Susan Liebman, a professor emerita and researcher, about her personal and professiona...
Continue reading
Precision patient finding has the potential to radically reduce the cost of trials and create a more centralized approach which serves to benefit a multitude of...
Continue reading
Clinical trials are essential for bringing new treatments to patients, but they’re not without challenges. Recruiting the right participants, staying on budget,...
Continue reading
Precision patient finding is an evolving field that is growing in line with the demands of precision medicine and rare disease research. Unlike traditional pati...
Continue reading
Implementing precision neurology comes with its own set of complexities—from decoding the brain's intricate workings to addressing the ethical challenges of usi...
Continue reading
In the latest episode of The Genetics Podcast, Patrick speaks with Dr. Jim Wilson, Professor of Human Genetics at the University of Edinburgh, about his work st...
Continue reading
Sano is proud to support Neuron23 in the NEULARK Phase 2 clinical trial, a groundbreaking study exploring NEU-411, a brain-penetrant LRRK2 inhibitor with the po...
Continue reading
Last week on The Genetics Podcast, Patrick Short sat down with Michelle Teng, CEO and co-founder of Etcembly, to explore her work at the intersection of immunot...
Continue reading
Precision medicine is transforming neurology by enabling more accurate diagnoses and tailored treatments. Here, we explore key components driving this progress,...
Continue reading
In a recent episode of The Genetics Podcast, host Patrick Short sits down with Eric Fauman, Executive Director and Head of Computational Biology in Pfizer's Int...
Continue reading
Millions of people worldwide are affected by neurological disorders like ALS, Alzheimer’s, and Parkinson’s. These conditions bring unique challenges for patient...
Continue reading
In the most recent episode of The Genetics Podcast, host Patrick Short speaks with Noam Baumatz, co-founder and CEO of Noga Therapeutics. Noam shares his deeply...
Continue reading
Today, the Lupus Research Alliance (LRA) launched the Data Repository, Exchange, and Analytics Platform (DREAM)—a pioneering knowledge-sharing platform dedicate...
Continue reading
In a recent webinar, former Reata Pharmaceuticals CEO Warren Huff shared his journey leading the company from its founding in 2002 to its landmark acquisition b...
Continue reading
Inherited retinal disorders (IRDs) are a diverse group of genetic eye conditions that impact millions worldwide, affecting light-sensitive cells in the retina a...
Continue reading
In the latest episode of The Genetics Podcast, Patrick welcomes back Dr. Veera Rajagopal, a drug discovery scientist at Regeneron, for his quarterly discussion ...
Continue reading
Inherited retinal diseases (IRDs) are a leading cause of genetic vision loss, yet they remain difficult to identify and diagnose. Genetic testing plays a pivota...
Continue reading
LONDON – 22 October 2024: Sano Genetics, the UK-based precision medicine company accelerating precision medicine clinical trials, has been named as one of Bloom...
Continue reading
Over 350 hereditary eye conditions are currently known, collectively affecting around one in every 1,000 people globally. These genetic disorders can influence ...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short interviews Mark Taylor, Head of Strategic Partnerships at the National Institute for Health an...
Continue reading
Genetic eye diseases present significant challenges for patients and healthcare providers alike. Conditions like retinitis pigmentosa, Stargardt disease, and Le...
Continue reading
A new partnership will bring together specialist eye care, genetic testing, and patient recruitment to advance both clinical research and care for people affect...
Continue reading
Chronic Kidney Disease (CKD) is a genetically heterogeneous condition, with over 60 genetic diseases known or suspected to affect the kidneys across both monoge...
Continue reading
In the latest episode of the Genetics Podcast, host Patrick Short spoke with Paul Wille, Director of Product Development at Abeona Therapeutics, about adeno-ass...
Continue reading
In a recent webinar hosted by Lindsey Wahlstrom-Edwards, Partnerships Lead at Sano Genetics, expert speakers explored the complexities of genetic testing and it...
Continue reading
On last week's episode of The Genetics Podcast, host Patrick Short was joined by Dr. Mike Snyder, Director of the Center for Genomics and Personalized Medicine ...
Continue reading
Precision medicine replaces the one-size-fits-all model of treatment and prevention with an approach that accounts for individual differences in genes, environm...
Continue reading
Precision medicine is reshaping healthcare by moving away from a one-size-fits-all approach to more personalized care. By understanding each patient's genetic m...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short welcomes Dr. Lon Cardon, CEO of the Jackson Laboratory, to discuss his career journey, the ris...
Continue reading
While precision medicine holds great promise for both patients and the growth of global markets, there are significant obstacles to be overcome to enable its wi...
Continue reading
As the global population ages, understanding the genetic, biological, social, and environmental factors influencing longevity has become a central area of resea...
Continue reading
In the latest episode of The Genetics Podcast, host Patrick Short welcomes Nadav Ahituv, Director of the Institute for Human Genetics at the University of Calif...
Continue reading
Breakthrough technologies and data innovation are driving cost reductions and increasing return on investment in precision medicine, fueling accelerated interna...
Continue reading
In this episode of The Genetics Podcast, host Patrick Short sits down with Marco Quarta, Co-founder and CEO of Rubedo Life Sciences, to discuss the biology of a...
Continue reading